Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era

Autor: Michael Oertel, MD, Dominik Hering, MSc, Nina Nacke, MSc, Christopher Kittel, MSc, Kai Kröger, MD, Jan Kriz, MD, Michael Fuchs, MD, Christian Baues, MD, Dirk Vordermark, MD, Rita Engenhart-Cabillic, MD, Klaus Herfarth, MD, Peter Lukas, MD, Heinz Schmidberger, MD, Simone Marnitz, MD, Peter Borchmann, MD, Andreas Engert, MD, Uwe Haverkamp, Hans Theodor Eich, MD

Publikováno v: Advances in Radiation Oncology, Vol 8, Iss 3, Pp 101169- (2023)

Purpose: Radiation therapy (RT) is an integral part of treatment concepts for early-stage Hodgkin lymphoma. This analysis reports on RT quality in the recent HD16 and 17 trials of the German Hodgkin Study Group (GHSG). Methods and Materials: All RT p

Externí odkaz: https://doaj.org/article/be482eea6f1c4df195be317ffeda2c0d

Predictive Value of Positron Emission Tomography/Computed Tomography After ABVD-Based Chemotherapy in Early-Stage Hodgkin Lymphoma.

Autor: Kobe C; Carsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Goergen H; Carsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Fuchs M; Carsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Müller H; Carsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Baues C; Carsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Engert A; Carsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Dietlein M; Carsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., von Tresckow B; Carsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Borchmann P; Carsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2019 Dec 01; Vol. 37 (34), pp. 3324-3325. Date of Electronic Publication: 2019 Sep 30.